Additional file 2: of Unique and shared inflammatory profiles of human brain endothelia and pericytes

Full secretome profiler dataset from Fig. 5. Pericytes or endothelia from two different cases were treated with either vehicle, or IL-1β (10 ng/mL) for 24 h before media were harvested and secretions analysed as per Fig. 5. Values represent intensity measurements from each secretion spot (two spots per secretion) from both biological replicates, from all treatment groups (Vehicle/Pericyte, IL-1β/Pericyte, Vehicle/Endothelial, IL-1β/Endothelial). Data are given in an Excel spreadsheet. (XLSX 41 kb

Additional file 1 of Involvement of the tumour necrosis factor receptor system in glioblastoma cell death induced by palbociclib-heptamethine cyanine dye conjugate

Additional file 1: Supplementary Figure 1. Cyclin-dependent kinase inhibitor-MHI-148 conjugates, 1 are not synergistic with TMZ. Patient-derived glioblastoma cells were treated with up to 100 μM of palbociclib, and 1 with and without 100 μM of TMZ for 96 h. Concentration-dependent effects of each compound on the toxicity of glioblastoma cells was measured by the percentage of Hoechst-positive cells after 96 h (EC50). A non-linear curve was fitted using Graphpad Prism using the concentration of each compound versus the percentage of hoechst-positive cells (A). Combination index (CI) was calculated from the CI equation algorithms using CompuSyn software. CI=1, 1 indicates additive effect, synergism, and antagonism, respectively (B). The pEC50 of each compound with and without TMZ (100 μM) on each glioblastoma cell line is summarised in B and D. The CI for palbociclib (A) and 1 (C), with TMZ across a range of effect sizes is presented per case. Data represents mean ±SEM for at least six independent glioblastoma cases, ns = p > 0.05. Supplementary Figure 2. Trafficking and expression of TNFR1 in response to 1 in patient-derived glioblastoma cells in the presence of vesicle trafficking inhibitor, BFA and protein translation inhibitor, CHX. Residual starting surface expression TNFR1 (Method A) (A). To investigate the net surface expression of TNFR1 (Method B) (B). C summarises method A and B detection of TNFR1. Total TNFR1 expression in response to 1 in the presence of absence of BFA or CHX (D) Summary data of the pEC50 (E) and Emax (F) of 1 on the total TNFR1 expression in the presence or absence of BFA or CHX. Basal total TNFR1 expression in G. Data represents mean ± SEM from three independent glioblastoma cases. ns = p > 0.05, * p < 0.05, ** p< 0.01, *** p < 0.001, One-way ANOVA relative to 1 plus vehicle inhibitor